Safety and efficacy results of a phase IV, open-label, multicenter, safety-monitoring study of icotinib in treating advanced non-small cell lung cancer (NSCLC): ISAFE study.

Fenlai Tan, Yan Sun, Yinxiang Wang et al.|Journal of Clinical Oncology|2013

Cited by 5